PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.
http://ww2.peerview.com
Unlocking the Benefits of Synergy Between Therapeutic Advances and Holistic Care in Gastric/GEJ Cancers: Current Evidence, Practical Guidance, and Point-of-Care Tools for Implementing a Multidisciplinary Approach to Modern Patient Care
Go online to PeerView.com/BBD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Targeted therapies have had a beneficial role in the advanced gastric or GEJ cancer setting, and several novel strategies of combining targeted therapy with immunotherapy are evolving the treatment landscape. While medicine continues to scientifically advance, the holistic care of patients with gastric/GEJ cancers is becoming more complex, and factors such as symptom management, psychological support, and nutritional considerations, in addition to effective treatment selection, need to be considered to offer the best clinical and quality of life outcomes to patients. This three-part educational activity offers learners an exclusive look at how science and care merge in the clinic to enhance the multidisciplinary, multidirectional management of patients with gastric/GEJ cancers. Upon completion of this activity, participants will be able to: Summarize clinical evidence on established targeted therapies, such as antiangiogenic agents, and emerging combination strategies, such as with checkpoint inhibitors, for advanced gastric or gastroesophageal junction (GEJ) cancers, Select appropriate second-line targeted therapies based on treatment history, patient preference, performance status, and biomarker status for patients with advanced gastric/GEJ cancers who have progressed following first-line chemotherapy, Develop a holistic treatment plan that addresses nutrition/diet concerns, emotional distress, treatment-related adverse events, and risk of disease progression, among other issues, with a multidisciplinary and interprofessional team of clinicians who care for patients with advanced gastric/GEJ cancers.